Current Report Filing (8-k)
December 01 2016 - 4:46PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT
TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): November 29, 2016
Arrowhead Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
0-21898
(Commission File Number)
|
|
|
Delaware
|
|
46-0408024
|
(State or other jurisdiction
of incorporation)
|
|
(IRS Employer
Identification No.)
|
225 South Lake Avenue, Suite 1050, Pasadena, CA 91101
(Address of principal executive offices) (Zip Code)
Registrants telephone number, including area code (626) 304-3400
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4(c)
|
Item 5.02
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
|
On November 29, 2016, Arrowhead Pharmaceuticals, Inc. (the Company) notified David Lewis, the Companys Chief Scientific Officer, that
his position will be terminated, effective December 13, 2016.
On November 29, 2016, the Company issued a press release announcing that the Company
will be discontinuing development of its clinical stage drug candidates ARC-520, ARC-521, and ARC-AAT, which utilize the DPC
iv
TM
, or EX1,
delivery vehicle and redeploying its resources to support the development of RNAi therapeutics that utilize the Companys proprietary subcutaneous and extra-hepatic delivery systems.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.
Date: December 1, 2016
|
|
|
ARROWHEAD PHARMACEUTICALS, INC.
|
|
|
By:
|
|
/s/ Kenneth Myszkowski
|
|
|
Kenneth Myszkowski
|
|
|
Chief Financial Officer
|
3
Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Historical Stock Chart
From Aug 2024 to Sep 2024
Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Historical Stock Chart
From Sep 2023 to Sep 2024